by Raynovich Rod | Oct 1, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech Stocks Hit New Highs Unfazed By Shutdown Biopharmaceutical stocks continued their blazing Q3 run today buoyed by assumptions that demand for pharmaceuticals will increase with 55 million new potential patients from Obamacare and that healthcare stocks are less...
by Raynovich Rod | Sep 26, 2013 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech Stocks Will Not Wait for Congress-Huge Rally Across the Board Analysts and Media are Piling On-Momentum Rules IBB up 1.75% XBI up 1.81% Rayno Biopharmaceuticals stocks are in a new leg up with large cap winners: Alexion (ALXN $115) up 2% Cubist (CBST $67.62)...
by Raynovich Rod | Sep 24, 2013 | 2024-25 Life Science Portfolios, Biopharmaceuticals
Life Science Sector at or Near YTD and All Time Highs Fidelity Fund (FBIOX) Outperform ETFs Over the past 3 years we reviewed how ETFs complement a biotechnology investment strategy and compared three of the largest and most liquid : FBT, IBB and XBI (see the...
by Raynovich Rod | Aug 18, 2013 | Biopharmaceuticals, Macro
Tempering, Tapering and Transition A mild sell-off shifted momentum to the bears last week as countercurrents and seasonality comes into play. Heavy vacations in August transition to Labor Day weekend, Jewish holidays then a pick up in trading by mid-September. Here...
by Raynovich Rod | Aug 15, 2013 | Biopharmaceuticals, Macro
Biotech Sector Momentum Quits-IBB at Support Level of $189 NASDAQ Off 1.73% to 3605 Have fund managers raised cash and gone on vacation? Moreover many weaker sectors have become leaders like gold, silver,materials and energy. Walmart and Cisco are leading the way...
by Raynovich Rod | Aug 6, 2013 | Biopharmaceuticals
Weakness in NASDAQ and Earnings Miss Gives an Excuse To Sell The Blistering 14% July Run in Biotech Comes to an End It was inevitable that something would cause biopharmaceutical stocks to falter. Today it was overall weakness in the market and a miss by the highest...
by Raynovich Rod | Aug 1, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Biotech ETF (IBB) Hits New High of $200-Mid Caps Get Turbo Boost Positive Economic Data Helps The life science sector roared ahead again today helped by a 1% move in NASDAQ now at YTD highs up 21%. With an earlier post last week we urged “staying the...
by Raynovich Rod | Jul 16, 2013 | Biopharmaceuticals
Biotech Stocks Take A Breather: NASDAQ off 0.3% at 3597 A little profit taking has set in after it seemed that the market would roar all summer. From the action in mid-cap biopharma stocks it looks like hedge funds are taking some off among high flyers.NASDAQ has been...
by Raynovich Rod | Jul 11, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools
Strong NASDAQ Up 1.35%-IBB Hits 188.82 All Time High A stealth rally that began with futures after the close yesterday was triggered by Bernanke comments interpreted by the market as backtracking on “tapering”. Maybe Bernanke was trying to soften his...
by Raynovich Rod | Jul 10, 2013 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
Rayno Life Science Movers 2% or more Alexion (ALXN $97.8) up 2.14% Amgen (AMGN $100.71) up 2.4% Pharmacyclics (PCYC $100.55) up 12% Vermillion (VRML $2.90) up 10.6% After a 4 day S&P rally up 2.7% stocks are taking a rest but the IBB ($183.56) rallied another...
